PMID- 27060436
OWN - NLM
STAT- MEDLINE
DCOM- 20170411
LR  - 20191210
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 125
DP  - 2016 Jun 5
TI  - Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma 
      by LC-MS/MS: Application to a clinical pharmacokinetic study.
PG  - 280-5
LID - S0731-7085(16)30189-3 [pii]
LID - 10.1016/j.jpba.2016.04.003 [doi]
AB  - Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type-B 
      (MAO-B) and has been used both as a monotherapy and in addition to levodopa in 
      the treatment of Parkinson's disease (PD). Rasagiline is metabolized by the 
      cytochrome P450 (CYP) system, and the following three major metabolites with 
      potential neuroprotective activity have been identified: 1-aminoindan (AI), 
      3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan 
      (3-OH-AI). In this study, a novel liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) method was developed for the simultaneous determination of rasagiline 
      and its major metabolites in human plasma. This method was validated in terms of 
      specificity, linearity, precision, accuracy, recovery, matrix effect and 
      stability. The validated method was then applied to a clinical pharmacokinetic 
      study after the oral administration of 1mg rasagiline mesylate tablets to six 
      healthy Chinese volunteers.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of 
      Drug Ministry of Education, West China School of Pharmacy, Sichuan University, 
      Chengdu 610041, Sichuan, China.
FAU - Yang, Leting
AU  - Yang L
AD  - Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of 
      Drug Ministry of Education, West China School of Pharmacy, Sichuan University, 
      Chengdu 610041, Sichuan, China.
FAU - Hua, Jing
AU  - Hua J
AD  - Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of 
      Drug Ministry of Education, West China School of Pharmacy, Sichuan University, 
      Chengdu 610041, Sichuan, China.
FAU - Xie, Huiru
AU  - Xie H
AD  - Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of 
      Drug Ministry of Education, West China School of Pharmacy, Sichuan University, 
      Chengdu 610041, Sichuan, China.
FAU - Jiang, Xuehua
AU  - Jiang X
AD  - Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of 
      Drug Ministry of Education, West China School of Pharmacy, Sichuan University, 
      Chengdu 610041, Sichuan, China.
FAU - Wang, Ling
AU  - Wang L
AD  - Department of Clinical Pharmacy and Pharmacy Administration, Key Laboratory of 
      Drug Ministry of Education, West China School of Pharmacy, Sichuan University, 
      Chengdu 610041, Sichuan, China. Electronic address: rebeccawang312@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20160401
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Indans)
RN  - 003N66TS6T (rasagiline)
SB  - IM
MH  - Chromatography, Liquid/*methods
MH  - Humans
MH  - Indans/*blood/pharmacokinetics
MH  - Reproducibility of Results
MH  - Tandem Mass Spectrometry/*methods
OTO - NOTNLM
OT  - Determination
OT  - Human plasma
OT  - LC-MS/MS
OT  - Metabolites
OT  - Rasagiline
EDAT- 2016/04/10 06:00
MHDA- 2017/04/12 06:00
CRDT- 2016/04/10 06:00
PHST- 2016/02/22 00:00 [received]
PHST- 2016/03/29 00:00 [revised]
PHST- 2016/04/01 00:00 [accepted]
PHST- 2016/04/10 06:00 [entrez]
PHST- 2016/04/10 06:00 [pubmed]
PHST- 2017/04/12 06:00 [medline]
AID - S0731-7085(16)30189-3 [pii]
AID - 10.1016/j.jpba.2016.04.003 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2016 Jun 5;125:280-5. doi: 10.1016/j.jpba.2016.04.003. Epub 
      2016 Apr 1.